Nursing specialists feel that there is a requirement for having a standard of practice in immunoglobulin therapy.
A review article published in the July/August 2005 Journal of Infusion Nursing examines the need for established treatment guidelines to support doctors and nurses in correctly dosing and administering intravenous immunoglobulin (IVIG) as replacement therapy in patients with primary immunodeficiency (PI) disorders, who do not produce adequate levels of antibodies essential in fighting infectious diseases.1
AdvertisementImmunoglobulin (IG) is a life-sustaining, blood plasma-derived product that has become standard immune replacement therapy for most people living with PI. Even as the use of IVIG therapy continues to expand, formal consensus is lacking within the medical community on the appropriate dosing and frequency of IVIG, according to the authors of the article.
The infusion therapy nursing specialists who authored the Journal of Infusion Nursing article, titled, "Developing Practice Guidelines for the Administration of Intravenous Immunoglobulin," offer an in-depth examination of all aspects of IVIG treatment, including the benefits and risks, and the roles of physicians, nurses and patients in achieving best results from therapy, as well as a comprehensive look at the expanding use of IVIG therapy and the associated clinical challenges.
Primary immunodeficiency encompasses more than 100 distinct inherited disorders that strike at the body's ability to fend off infection.2 IG replacement therapy can be life-saving and offers substantially improved health and quality of life for most living with a PI disorder.
Globally, IG treatments can be administered by intravenous infusion, intramuscular injections, or subcutaneous infusion. In the US, intravenous administration is currently the most common mode. However, as many as one-fourth of all PI patients have problems with IVIG because of poor access to veins or severe side effects from the therapy.3 Another option is administering IG subcutaneously, or under the skin (SC). In Europe, SCIG has been approved and is regularly used for certain indications. In the Scandinavian countries, particularly Sweden, the SC route of administration has been widely adopted.
Although SCIG must be given more frequently than IVIG, clinical trials have demonstrated that it can be self-administered at home without the assistance of a doctor or nurse.
You May Also Like